Future Landscape of Chronic GVHD


Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.

This is a video synopsis of a discussion involving Dr Yi-Bin Chen, Director of the Transplant and Cell Therapy Program at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School; Dr Corey Cutler, Director of the Stem Cell Transplant Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School; Dr Mitchell Horwitz, Professor of Medicine Director of the Adult Blood and Marrow Transplant Program at Duke University, and Dr Hannah Choe, Assistant Professor and Director of the Graft-versus-Host-Disease (GVHD) program at Ohio State University.

The panelists share their predictions for the future of chronic GVHD in the next 3 to 5 years.

Dr Horwitz anticipates significant progress in the management of chronic GVHD, with a focus on moving effective agents to earlier stages of treatment to reduce patient exposure to corticosteroids. Dr Choe echoes this sentiment, expressing enthusiasm for the possibility of eliminating frontline corticosteroids. Dr Choe also highlights the potential of preemptive strategies, citing Dr Corey Cutler's presentation on using pinatuzumab in a preemptive manner, emphasizing the importance of early intervention.

Dr Cutler foresees two major developments. Firstly, he expects the use of effective drugs not only earlier in treatment but also in preventative strategies, hinting at a potential shift towards primary prevention of chronic GVHD. Secondly, he expresses hope for advancements in personalized medicine, leveraging artificial intelligence or biomarker studies to match the right patient with the right drug, ultimately moving away from FDA guidance towards biologic guidance.

Dr Chen emphasizes the ongoing shift in GVHD prophylaxis trials towards preventing chronic GVHD as the main focus. He acknowledges the challenges but sees it as a positive step to improve outcomes.

The panelists collectively look forward to a future where innovative therapies allow for the removal of steroids from first-line treatments, improved response rates, and more effective strategies for managing chronic GVHD.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Alessandra Ferrajoli, MD
Video 16 - "Trajectory of Evolving HCC Treatment Landscape"